Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
José Manuel Garcia-Dominguez, Delicias Muñoz, Marta Comellas, Irmina Gonzalbo, Luis Lizán & Carlos Polanco Sánchez. (2016) Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Preference and Adherence 10, pages 1945-1956.
Read now
Read now
Luis Hernandez, Shien Guo, Elizabeth Kinter & Monica Fay. (2016) Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of Medical Economics 19:7, pages 684-695.
Read now
Read now
Danny Decoo & Mathieu Vokaer. (2015) Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. Patient Preference and Adherence 9, pages 1669-1676.
Read now
Read now
Antonios Bayas & Mathias Mäurer. (2015) Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence. Patient Preference and Adherence 9, pages 265-274.
Read now
Read now
Jong-Mi Lee & May H Han. (2015) Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod. Patient Preference and Adherence 9, pages 685-693.
Read now
Read now
Elisabetta Verdun di Cantogno, Mark Tomlinson, Laure Manuel & Kunal Thakur. (2014) Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA. Pragmatic and Observational Research 5, pages 53-64.
Read now
Read now
Articles from other publishers (7)
Jagadeswara R. Earla, Rutugandha Paranjpe, Nandita Kachru, George J. Hutton & Rajender R. Aparasu. (2020) Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Research in Social and Administrative Pharmacy 16:12, pages 1670-1676.
Crossref
Crossref
E. Yu. Tsareva, O. O. Favorova, A. N. Boyko & O. G. Kulakova. (2019) Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis. Molecular Biology 53:4, pages 513-534.
Crossref
Crossref
Daniel M. HartungKirbee A. JohnstonAdriane IrwinSheila MarkwardtDennis N. Bourdette. (2019) Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. Health Affairs 38:2, pages 303-312.
Crossref
Crossref
Elaine Cameron, David Rog, Gavin McDonnell, James Overell, Owen Pearson & David P. French. (2019) Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study. Multiple Sclerosis and Related Disorders 27, pages 378-382.
Crossref
Crossref
Ingrid E. H. Kremer, Silvia M. A. A. Evers, Peter J. Jongen & Mickaël Hiligsmann. (2018) Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling. Health Expectations 21:1, pages 171-180.
Crossref
Crossref
Tessa Eagle, Fiona Stuart, Alicia S. Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L. Cook, Tanuja Chitnis, Howard L. Weiner, Bonnie I. Glanz & Brian C. Healy. (2017) Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders 18, pages 196-201.
Crossref
Crossref
Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, Jeremy Hobart, Gisela Kobelt, George Pepper, Maria Pia Sormani, Christoph Thalheim, Anthony Traboulsee & Timothy Vollmer. (2016) Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders 9, pages S5-S48.
Crossref
Crossref